Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Verastem, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for cancer, with a primary emphasis on rare and genetically defined oncology indications. The company operates within the biotechnology and oncology therapeutics industries, developing small-molecule drugs designed to inhibit key signaling pathways involved in tumor growth and survival. Its core strategy centers on precision medicine approaches that address high-unmet-need patient populations.
The company’s principal product candidate is avutometinib (formerly VS-6766), a dual RAF/MEK inhibitor, being developed primarily in combination regimens for RAS/MAPK pathway–driven cancers, including low-grade serous ovarian cancer (LGSOC). Verastem was founded in 2010 as a spinout from academic research associated with stem cell biology and cancer resistance mechanisms and has since evolved into a focused oncology development company, advancing late-stage clinical programs after earlier pipeline rationalization.
Business Operations
Verastem’s operations are centered on drug discovery, clinical development, regulatory strategy, and preparation for potential commercialization. The company generates no significant commercial revenue and is primarily funded through equity offerings, strategic collaborations, and milestone-based payments. Its lead development programs include avutometinib and defactinib, a FAK inhibitor, which are often studied in combination to address resistance pathways in solid tumors.
The company conducts clinical trials globally, with operational activities spanning the United States and select international trial sites. Verastem controls its core intellectual property related to its drug candidates and relies on contract research organizations for clinical execution. A key strategic collaboration includes a partnership with Roche’s Genentech unit, which supports combination studies involving targeted oncology agents.
Strategic Position & Investments
Strategically, Verastem is focused on advancing late-stage clinical development in indications with defined biomarkers and limited treatment options, aiming to streamline regulatory approval pathways. Its most advanced program targets recurrent LGSOC, where it has reported positive clinical data that have supported regulatory discussions. The company’s growth initiatives prioritize combination therapies and label expansion within RAS/MAPK-driven cancers.
Verastem has made targeted investments in expanding its clinical pipeline rather than broad-based acquisitions, maintaining a capital-efficient structure. The company does not operate a diversified subsidiary portfolio; instead, it concentrates resources on its core assets, avutometinib and defactinib, while exploring additional combination opportunities with external partners in emerging oncology treatment paradigms.
Geographic Footprint
Verastem is headquartered in the United States, with its principal executive offices in Boston, Massachusetts, a major biotechnology hub. Its primary operational footprint is North America, where corporate management, research oversight, and regulatory activities are based.
Internationally, Verastem maintains a presence through clinical trial operations in Europe and other global regions to support patient enrollment and regulatory alignment. While it does not maintain extensive foreign infrastructure, its international clinical activities provide global exposure and support potential future commercialization strategies outside the United States.
Leadership & Governance
Verastem is led by an executive team with experience in oncology drug development, regulatory affairs, and biotechnology commercialization. The leadership emphasizes disciplined capital allocation, biomarker-driven development, and strategic partnerships to advance therapies efficiently through late-stage trials.
Key executives include:
- Dan Paterson – President and Chief Executive Officer
- Robert A. Forrester, MD – Chief Medical Officer
- John J. Ryan – Chief Financial Officer
- Andrew J. McDonald – Chief Operating Officer
- Daniel R. Flynn – General Counsel and Corporate Secretary
The company is governed by a board of directors with backgrounds in biotechnology, finance, and pharmaceutical development, supporting a strategy focused on long-term value creation through targeted oncology innovation.